CTLA4 and cancer: Despite recent successes in cancer immunotherapy harnessing programmed death-1 (PD-1) (1–5) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) immune checkpoint inhibitors (6), significant limitations exist for the antibody-based immunotherapies.